Ergoteles’s Accelerate Diagnostics AXDX Stock Holding History

Ergoteles’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,230	Closed	-$131K	–	1546
2022 Q2	$131K	Buy	+13,230	New	+$117K	﹤0.01%	1449

Other funds holding AXDX

GAM

Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Ergoteles's AXDX Position: Q3 2022 in Review

Ergoteles sold out of Accelerate Diagnostics (AXDX) in Q3 2022, closing a stake of 13,230 shares — an estimated $131K sold.

Ergoteles first reported a position in AXDX in Q2 2022 and held it in 1 quarter. The position peaked at $131K in Q2 2022. 84 funds tracked by Wall St. Rank hold AXDX as of Q3 2022.

Ergoteles reported no remaining Accelerate Diagnostics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 13,230 Accelerate Diagnostics shares in Q3 2022, an estimated $131K.
Ergoteles first reported a position in Accelerate Diagnostics in Q2 2022 and held it in 1 quarter.
Ergoteles's Accelerate Diagnostics position peaked at $131K in Q2 2022.
84 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.